EUVIMEDEUVIMED entdecken
Crossref

Synthesis, Characterization, Bioevaluation, and Docking Studies of Spiroisatin‐Based Hydrazide Conjugates

Muhammad Imran Ali iD, Habiba Nazir, David Mross, Klaus Jurkschat iD, Muhammad Moazzam Naseer iD

Chemistry & Biodiversity · 2025

DOI: 10.1002/cbdv.202403440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2025. Verfasst von Muhammad Imran Ali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Antineoplastic Agents, Hydrazines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A series of spiroisatin‐based hydrazide conjugates IV(a–t) was synthesized and structurally characterized using spectral data, with compound IV‐a further confirmed by x‐ray diffraction analysis. All the synthesized compounds were evaluated for their biological potential in a cell painting assay. Among the synthesized spiroisatin derivatives, compound IV‐p exhibited significant activity in inducing cellular morphological changes, with an induction value of 30.6%. In addition, some compounds showed high biosimilarities with marketed drugs. Specifically, the compounds IV‐n and IV‐p showed a high biosimilarity with the orally active iron chelator deferasirox, and IV‐m showed a high biosimilarity with the kinase inhibitor alisertib. Furthermore, compounds IV‐p showed significant inhibition against human breast cancer (MDA‐MB‐231 = 82.37%) and colorectal carcinoma cell lines (HCT‐116 = 86.25%) during preliminary investigations. Moreover, it was revealed through molecular docking analysis that IV‐p possesses a good binding score against ferroportin and Aurora A kinase (−9.3 and −9.2 kcal/mol), which are quite comparable with the deferasirox (−9.2 kcal/mol) and alisertib (−9.8 kcal/mol). Pharmacokinetic studies revealed that the synthesized conjugates have good oral bioavailability, balanced hydrophilicity, and minimal toxicity. The results of this study clearly highlight the potential of these conjugates as promising small bioactive molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationAntineoplastic AgentsHydrazinesProtein Kinase InhibitorsSpiro CompoundsHumansStructure-Activity RelationshipCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugAnimalsAurora Kinase A

Stichwörter der Autor:innen

antiproliferative activitycell painting assaydrug‐likenessmolecular dockingspiroisatin‐based hydrazide conjugatessynthesis

Substanzen

Antineoplastic AgentsHydrazinesProtein Kinase InhibitorsSpiro CompoundsAurora Kinase A

Autor:innen und Institutionen

  • Department of Chemistry, Quaid-i-Azam University, Islamabad, Pakistan.
  • Department of Radiological Sciences and Imaging Technology, Ibadat International University Islamabad (Pakpattan Campus), Pakistan.
  • Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.

ORCID-Profile: Muhammad Imran Ali, Klaus Jurkschat, Muhammad Moazzam Naseer

Zitieren

APA

Ali, M. I., Nazir, H., Mross, D., Jurkschat, K., & Naseer, M. M. (2025). Synthesis, Characterization, Bioevaluation, and Docking Studies of Spiroisatin‐Based Hydrazide Conjugates. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202403440

Vancouver

Ali MI, Nazir H, Mross D, Jurkschat K, Naseer MM. Synthesis, Characterization, Bioevaluation, and Docking Studies of Spiroisatin‐Based Hydrazide Conjugates. Chemistry & Biodiversity. 2025. doi:10.1002/cbdv.202403440

BibTeX
@article{Ali2025,
  author = {Ali, Muhammad Imran and Nazir, Habiba and Mross, David and Jurkschat, Klaus and Naseer, Muhammad Moazzam},
  title = {Synthesis, Characterization, Bioevaluation, and Docking Studies of Spiroisatin‐Based Hydrazide Conjugates},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  doi = {10.1002/cbdv.202403440}
}
Kostenlos starten →